Amedisys (AMED) Tops Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Amedisys (AMED) Could Help Transform Healthcare - Mizuho
March 10, 2016 7:39 AM ESTMizuho analyst, Sheryl Skolnick, thinks Amedisys Inc's (NASDAQ: AMED) turnaround continues to impress as it proceeds on multiple fronts, driving better than expected 4Q15 results, meaningful 2016 improvements and likely strong 2017 growth. Increasing transparency into the progress, costs, timing and returns to the turnaround strategies are making the Street increasingly confident and supported a strong move in the stock. The analyst thinks AMED is strongly positioned not only as a post-acute... More
